10x Genomics (TXG) Capital Expenditures (2018 - 2026)

10x Genomics has disclosed Capital Expenditures across 9 years of filings, most recently posting $1.6 million for Q2 2026.

• In Q2 2026, Capital Expenditures rose 0.63% year-over-year to $1.6 million; the TTM figure through Jun 2026 stood at $5.6 million (down 43.94% YoY), while the FY2025 annual figure was $5.9 million, down 52.11% from the prior year.
• Capital Expenditures came in at $1.6 million for Q2 2026 at 10x Genomics, down from $1.6 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $39.7 million in Q4 2022 to a low of -$753000.0 in Q2 2023.
• Average Capital Expenditures over 5 years is $11.2 million, with a median of $2.9 million recorded in 2024.
• Year-over-year, Capital Expenditures sank 102.77% in 2023 and soared 482.2% in 2024.
• Over 5 years, Capital Expenditures stood at $39.7 million in 2022, then plunged by 91.32% to $3.4 million in 2023, then retreated by 21.28% to $2.7 million in 2024, then tumbled by 34.57% to $1.8 million in 2025, then fell by 10.64% to $1.6 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $1.6 million in Q2 2026, $1.6 million in Q1 2026, and $1.8 million in Q4 2025.